PE20180801A1 - Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa - Google Patents

Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa

Info

Publication number
PE20180801A1
PE20180801A1 PE2018000183A PE2018000183A PE20180801A1 PE 20180801 A1 PE20180801 A1 PE 20180801A1 PE 2018000183 A PE2018000183 A PE 2018000183A PE 2018000183 A PE2018000183 A PE 2018000183A PE 20180801 A1 PE20180801 A1 PE 20180801A1
Authority
PE
Peru
Prior art keywords
sulfatase
compositions
methods
iduronate
supplying
Prior art date
Application number
PE2018000183A
Other languages
English (en)
Inventor
Gaozhong Zhu
Kris Lowe
Zahra Shahrokh
James Christian
Rick Fahrner
Jing Pan
Teresa Leah Wright
Pericles Calias
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45352777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of PE20180801A1 publication Critical patent/PE20180801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)

Abstract

Referido a una formulacion para via intratecal que comprende una proteina iduronato-2-sulfatasa (I2S) a una concentracion que varia de 5-300 mg/ml y fosfato, en donde el fosfato esta presente a una concentracion de hasta 50mM. Tambien se refiere a composiciones y metodos para suministro al CNS de enzimas lisosomales para tratamiento efectivo de enfermedades de almacenamiento lisosomal como el tratamiento de Sindrome de Hunters.
PE2018000183A 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa PE20180801A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
PE20180801A1 true PE20180801A1 (es) 2018-05-09

Family

ID=45352777

Family Applications (8)

Application Number Title Priority Date Filing Date
PE2012002498A PE20130648A1 (es) 2010-06-25 2011-06-25 Tratamiento del sindrome de sanfilippo tipo b
PE2012002479A PE20130637A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos
PE2018000183A PE20180801A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2012002475A PE20130579A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2017000503A PE20170938A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos
PE2012002474A PE20130578A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
PE2012002476A PE20130589A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE2017001612A PE20180130A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2012002498A PE20130648A1 (es) 2010-06-25 2011-06-25 Tratamiento del sindrome de sanfilippo tipo b
PE2012002479A PE20130637A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos

Family Applications After (5)

Application Number Title Priority Date Filing Date
PE2012002475A PE20130579A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2017000503A PE20170938A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos
PE2012002474A PE20130578A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
PE2012002476A PE20130589A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE2017001612A PE20180130A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a

Country Status (24)

Country Link
US (14) US9814764B2 (es)
JP (21) JP6250616B2 (es)
CN (4) CN104857504A (es)
AR (6) AR081680A1 (es)
BR (1) BR112012033214B1 (es)
CA (1) CA3171308A1 (es)
CL (7) CL2012003657A1 (es)
DK (3) DK3626258T3 (es)
ES (3) ES2896060T3 (es)
HK (2) HK1214149A1 (es)
HR (3) HRP20211660T1 (es)
HU (6) HUE052944T2 (es)
LT (3) LT3626257T (es)
MX (1) MX354776B (es)
NZ (2) NZ702803A (es)
PE (8) PE20130648A1 (es)
PL (1) PL2588130T3 (es)
PT (6) PT3626258T (es)
RS (3) RS62520B1 (es)
RU (1) RU2761342C2 (es)
SI (3) SI3626258T1 (es)
SM (1) SMT201600385B (es)
TW (8) TW201701899A (es)
UA (2) UA125060C2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
SI2485761T1 (sl) 2009-10-09 2019-05-31 Armagen, Inc. Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
ES2650689T3 (es) 2010-06-25 2018-01-19 Shire Human Genetic Therapies, Inc. Administración de agentes terapéuticos al sistema nervioso central
CA3171308A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of iduronate-2-sulfatase
CN103282046B (zh) 2010-06-25 2015-05-13 夏尔人类遗传性治疗公司 芳基硫酸酯酶 a cns 递送的方法和组合物
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
US20220133863A1 (en) * 2010-06-25 2022-05-05 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
JP6266529B2 (ja) 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおけるアリールスルファターゼａ活性を増加するための方法および組成物
BR112014015352A8 (pt) 2011-12-23 2017-06-13 Shire Human Genetic Therapies tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
SG11201509419QA (en) * 2013-05-15 2015-12-30 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3292206B8 (en) 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
CN108430494A (zh) * 2015-12-30 2018-08-21 株式会社绿十字 用于治疗亨特综合征的方法和组合物
AU2017222620B2 (en) * 2016-02-24 2022-06-16 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
SG10201912761UA (en) 2016-04-15 2020-02-27 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
US20200397703A1 (en) * 2018-02-28 2020-12-24 Seikagaku Corporation Package and method for producing the same
CN108534695A (zh) * 2018-05-04 2018-09-14 无锡恩特卫自动化检测设备有限公司 一种基于机器视觉系统的瓶塞漏酒检测方法及装置
KR20210024082A (ko) 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253770B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
IL302029A (en) 2020-10-14 2023-06-01 Denali Therapeutics Inc Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof
CN113283465B (zh) * 2021-04-02 2022-04-29 电子科技大学 一种弥散张量成像数据分析方法及装置
CN115116623A (zh) * 2022-06-28 2022-09-27 深圳市儿童医院 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133001A (en) * 1959-11-26 1964-05-12 Muset Pedro Puig Stabilization of enzymes
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
CN1163264C (zh) * 1993-02-02 2004-08-25 爱克索马技术有限公司 改进的药物组合物
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
ATE225184T1 (de) 1997-08-22 2002-10-15 Seikagaku Kogyo Co Ltd Arzneimittel zur behandlung von durch hernie gestörter intervertebraler bandscheibe
WO2000034451A1 (en) 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6368315B1 (en) 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US20020099025A1 (en) * 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) * 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
DE60224816T2 (de) 2001-04-30 2009-01-22 ZyStor Therapeutics, Inc., Milwaukee Subzelluläres targeting von therapeutischen proteinen
WO2003102583A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2463473A1 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Targeted therapeutic proteins
WO2003068159A2 (en) 2002-02-11 2003-08-21 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
DK1503788T3 (da) * 2002-04-25 2011-10-17 Shire Human Genetic Therapies Behandling af alpha-galactosidase A-deficiens
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
CA2814767C (en) 2003-01-31 2016-03-15 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
US8026209B2 (en) 2003-02-10 2011-09-27 Bbb Holding B.V. Methods and compositions for targeting agents into and across the blood-barrier and other endothelial cell microvascular barriers
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AU2004253471B2 (en) 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
ES2687671T3 (es) 2004-01-30 2018-10-26 Shire Pharmaceuticals Ireland Limited Arilsulfatasa A recombinante para reducir los niveles de galatosil sulfátidos en un sujeto
WO2005074888A2 (en) 2004-02-03 2005-08-18 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
US20080014188A1 (en) 2004-02-06 2008-01-17 Zankel Todd C Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
EP1716232B9 (en) 2004-02-10 2010-10-13 ZyStor Therapeutics , Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CN101310011A (zh) 2004-06-15 2008-11-19 巴克斯特国际公司 固相微颗粒治疗剂的离体应用
JP2008516190A (ja) * 2004-08-11 2008-05-15 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 酵素に基づく時間・温度インジケーター
IL165334A0 (en) * 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
JPWO2006121199A1 (ja) * 2005-05-11 2008-12-18 日本ケミカルリサーチ株式会社 脂質小胞体組成物
ES2485369T3 (es) 2005-06-08 2014-08-13 Amicus Therapeutics, Inc. Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
PT1988823T (pt) * 2006-02-09 2018-11-22 Genzyme Corp Administração intraventricular lenta
CA2882501C (en) 2006-04-04 2021-09-07 Zymenex A/S Compositions comprising alpha mannosidase and uses thereof
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US20080140008A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
US20090041741A1 (en) 2007-03-06 2009-02-12 Saint Louis University Modified enzyme and treatment method
WO2009017005A1 (ja) 2007-07-27 2009-02-05 Sharp Kabushiki Kaisha 移動局装置、基地局装置、通信システム及びプログラム
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
US8470771B2 (en) * 2007-11-14 2013-06-25 Institute Of Microbiology, Chinese Academy Of Sciences Method and medicament for inhibiting the infection of influenza virus
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
EP3778652A1 (en) 2008-05-07 2021-02-17 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
CN103282046B (zh) 2010-06-25 2015-05-13 夏尔人类遗传性治疗公司 芳基硫酸酯酶 a cns 递送的方法和组合物
CA3171308A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of iduronate-2-sulfatase
JP6073783B2 (ja) * 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
EP3964229A1 (en) 2010-06-25 2022-03-09 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of iduronate-2-sulfatase
WO2011163651A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
NZ605871A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
ES2650689T3 (es) * 2010-06-25 2018-01-19 Shire Human Genetic Therapies, Inc. Administración de agentes terapéuticos al sistema nervioso central
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
US8580922B2 (en) * 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
WO2013096899A2 (en) * 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a

Also Published As

Publication number Publication date
AR081678A1 (es) 2012-10-10
JP2023099216A (ja) 2023-07-11
US20140271598A1 (en) 2014-09-18
RS62620B1 (sr) 2021-12-31
DK3626258T3 (da) 2021-09-20
JP2019038853A (ja) 2019-03-14
HUE055963T2 (hu) 2022-01-28
LT3103469T (lt) 2021-03-25
PE20130589A1 (es) 2013-05-19
JP6797876B2 (ja) 2020-12-09
PL2588130T3 (pl) 2017-09-29
HRP20211660T1 (hr) 2022-02-04
JP2021181489A (ja) 2021-11-25
PE20130578A1 (es) 2013-05-19
TW201206465A (en) 2012-02-16
PT3626258T (pt) 2021-10-19
ES2896060T3 (es) 2022-02-23
SI3103469T1 (sl) 2021-04-30
JP2016040337A (ja) 2016-03-24
HUE056884T2 (hu) 2022-03-28
AR082025A1 (es) 2012-11-07
JP6522073B2 (ja) 2019-05-29
US11471516B2 (en) 2022-10-18
US10646554B2 (en) 2020-05-12
HRP20211520T1 (hr) 2021-12-24
JP2017214434A (ja) 2017-12-07
CN104857504A (zh) 2015-08-26
US9814764B2 (en) 2017-11-14
CL2012003657A1 (es) 2013-04-19
JP2023052868A (ja) 2023-04-12
US20170042978A1 (en) 2017-02-16
JP2023062114A (ja) 2023-05-02
JP2018002735A (ja) 2018-01-11
LT3626257T (lt) 2021-12-10
CN105233277A (zh) 2016-01-13
JP2019006826A (ja) 2019-01-17
CL2020000468A1 (es) 2020-09-04
HRP20210298T1 (hr) 2021-04-16
CL2017002488A1 (es) 2017-12-15
US20180071212A1 (en) 2018-03-15
SI3626257T1 (sl) 2021-12-31
US9220677B2 (en) 2015-12-29
PT3626257T (pt) 2021-11-12
CA3171308A1 (en) 2011-12-29
TWI602573B (zh) 2017-10-21
US20200046810A1 (en) 2020-02-13
CL2012003656A1 (es) 2013-07-19
US20160158324A1 (en) 2016-06-09
AR081677A1 (es) 2012-10-10
TW202112391A (zh) 2021-04-01
RU2018113327A (ru) 2019-03-01
ES2895655T3 (es) 2022-02-22
TW201212936A (en) 2012-04-01
TWI609694B (zh) 2018-01-01
JP6346162B2 (ja) 2018-06-20
CN106139133A (zh) 2016-11-23
US20200113981A1 (en) 2020-04-16
PE20130648A1 (es) 2013-07-03
PT2593131T (pt) 2019-10-30
TW201825111A (zh) 2018-07-16
PE20170938A1 (es) 2017-07-13
TW201815411A (zh) 2018-05-01
AR081681A1 (es) 2012-10-10
PT2585104T (pt) 2019-10-30
MX354776B (es) 2018-03-20
JP2018002734A (ja) 2018-01-11
TWI698252B (zh) 2020-07-11
US11065308B2 (en) 2021-07-20
BR112012033214B1 (pt) 2020-11-03
US20200405825A1 (en) 2020-12-31
UA125060C2 (uk) 2022-01-05
US20170042977A1 (en) 2017-02-16
JP6285409B2 (ja) 2018-02-28
CN106139133B (zh) 2020-12-04
JP2020079244A (ja) 2020-05-28
RU2018113327A3 (es) 2021-07-21
US20230165942A1 (en) 2023-06-01
RU2018137304A3 (es) 2022-02-22
US20220133862A1 (en) 2022-05-05
JP2021167341A (ja) 2021-10-21
SMT201600385B (it) 2017-03-08
TW201726161A (zh) 2017-08-01
PT2588130T (pt) 2016-11-25
JP2016094451A (ja) 2016-05-26
MX2013000321A (es) 2013-04-03
JP2016040335A (ja) 2016-03-24
JP7448507B2 (ja) 2024-03-12
HUE046856T2 (hu) 2020-03-30
PE20180130A1 (es) 2018-01-18
PE20130637A1 (es) 2013-06-13
RU2018137304A (ru) 2019-03-21
CL2016003159A1 (es) 2017-05-12
SI3626258T1 (sl) 2021-11-30
TW202337489A (zh) 2023-10-01
US11065307B2 (en) 2021-07-20
NZ702800A (en) 2017-03-31
UA125743C2 (uk) 2022-06-01
AR081680A1 (es) 2012-10-10
JP7087175B2 (ja) 2022-06-20
US20180085438A1 (en) 2018-03-29
JP2022024176A (ja) 2022-02-08
RU2017125281A (ru) 2019-01-31
NZ702803A (en) 2017-05-26
JP6938456B2 (ja) 2021-09-22
JP2016037504A (ja) 2016-03-22
JP2020079298A (ja) 2020-05-28
JP6522072B2 (ja) 2019-05-29
PT3103469T (pt) 2021-03-04
RU2017125281A3 (es) 2020-11-09
RS62520B1 (sr) 2021-11-30
CN105664142A (zh) 2016-06-15
JP6250616B2 (ja) 2017-12-20
HUE052944T2 (hu) 2021-05-28
HK1218719A1 (zh) 2017-03-10
DK3626257T3 (da) 2021-11-08
US20130295077A1 (en) 2013-11-07
BR112012033214A2 (pt) 2017-05-23
PE20130579A1 (es) 2013-05-19
HUE046409T2 (hu) 2020-02-28
CN105233277B (zh) 2019-01-01
HUE031036T2 (en) 2017-06-28
US11260112B2 (en) 2022-03-01
CL2012003654A1 (es) 2013-06-14
CL2012003655A1 (es) 2013-04-19
JP2020079297A (ja) 2020-05-28
AR081679A1 (es) 2012-10-10
TWI790444B (zh) 2023-01-21
RU2761342C2 (ru) 2021-12-07
JP2016041755A (ja) 2016-03-31
TWI669128B (zh) 2019-08-21
US10456454B2 (en) 2019-10-29
US20190183984A1 (en) 2019-06-20
JP2021167340A (ja) 2021-10-21
US20230026836A1 (en) 2023-01-26
HK1214149A1 (zh) 2016-07-22
RS61683B1 (sr) 2021-05-31
JP2019031575A (ja) 2019-02-28
ES2858726T3 (es) 2021-09-30
JP6466538B2 (ja) 2019-02-06
JP6898909B2 (ja) 2021-07-07
DK3103469T3 (en) 2021-02-22
TW201701899A (zh) 2017-01-16
JP7359827B2 (ja) 2023-10-11
LT3626258T (lt) 2021-12-10

Similar Documents

Publication Publication Date Title
PE20180801A1 (es) Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
CY1122307T1 (el) Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς
CY1124910T1 (el) Μεθοδοι και συνθεσεις για παραδοση στο κνς της αρυλοσουλφατασης α
CO6321263A2 (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
NZ702050A (en) 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
NZ605874A (en) Methods and compositions for cns delivery of heparan n-sulfatase
UA112065C2 (uk) Похідні імідазолу як інгібітори ферменту pde10a
GT201200180A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
CO6612245A2 (es) Derovados de fenilmidazol heteroaromáticos como inhibidores de enzima pde10a
GT201200193A (es) Derivados de aril triazol heteroarmoaticos como inhibidores de enzima pde10a
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
EA201491578A1 (ru) Подкожное введение идуронат-2-сульфатазы
MX2013013098A (es) Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
AR124399A2 (es) Formulaciones estables para la administración intratecal de iduranato-2-sulfatasa
PH12014501434A1 (en) Quinoline derivatives as pde10a enzyme inhibitors
MA37931A1 (fr) Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
DOP2013000108A (es) Derivados de imidazol como inhibidores de la enzima pde10a